|
|
|
|
2) Longo WE, Rigler W and Slade J. Crocidolite asbestos fibers in smoke from original Kent sigarettes. Canc Res 55:2232-2235, 1995. 3) Fraumeni JF Jr, Ederer F and Miller RW. An evaluation of the corcinogenicity of simian virus 40 inman. JAMA 185: 713-718, 1963. 4) Cicala C, Pompetti F and Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 142: 1524-1533,1993. 5) Rush V. International Mesothelioma Insterest Group. A proposed new international TNM stating system for malignant pleural mesothelioma. Chest 1995; 108:1122-8. 11) World Health Organization: Handobook for reporting results of cancer treatment. WHO offset publication no.48. Geneva, Switzerland, World Health Organization,1979. 6) Sugarbaker DJ and Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 113(1): 61s - 64s, 1998. 7) Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 20 : 433 - 438, 1991. 8) Bisset D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. J Clin Oncol 3: 315- 317, 1991. 9) Kutcher Gj, Kestler C, Greenblatt D et al. Technique for external beam treatment for mesothelioma. Int. J Radiat Oncol Biol Phys 13: 1747 - 1752, 1987. 10) Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 13: 4 - 9, 1990. 11) Mattson K, Giaccone G, Kirkparick A et al. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10: 824 - 828, 1992. 12) Zidar BL, Green S., Pierce HI et al. A phase II evaluation of cispalit in unresectable diffuse malignant mesothelioma : A South-West Oncology Group Stuty. Invest New Drugs 6 : 223 - 226, 1988. 13) FalKson G, Hunt M, Borden EC et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 10: 337 - 343, 1992. 14) Zidar BL, Metch B, BalcerzaK SP et al. A phase II evaluation of infosfamide and mèsna in unresectable diffusue malignant mesothelioma. A Southwest Oncology Group study. Cacer 70: 2547 - 2551, 1992. 15) Alberts AS, Falkson G and Zyl LV. Malignant pleural mesothelioma: Phase II pilot study of ifostamide and mesna. J Natl Cancer Inst 80: 968 - 970,1988. 16) Vogelzang NJ Hrndon J and Clamon GH. paclitaxel ( Taxol) for malignant mesothelioma (MM): A phase II study of the Cancer and Leukemia Group B (CALGB 9234). Proc Soc Clin Oncol 13: 405 1994 (absts 1382). 17) Chahinian AP, Antman K, Goutsou et al. Randomized phase II trial of cisplatin With mitomycin od doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.J Cin Oncol 11 (8) : 1559- 1565, 1993. 18) Byrne M J, Davidson J A, Musk A W, et al. Cisplatin and Gemcitabine treatment for malignant mosothelioma. A Phase II study. J Clin Oncol 17 (1) 1999: 25 -3224. 19) Fizazi K, Caliandro R, Soulie P. Combination raltitrexed (Tomudex(R)-oxaliplatin: a step for the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemoimmunotherapy in mesothelioma. 20) Vogelzang N, Taub R, Shin D, et al. Phase II randomized trial of Onconase(Onc) vs Doxorubicin (Dox) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis and survival. 21) Hilaris BS, Dattatreyudu N, Kwong E et al. Pleurectomy and intraoperative brachitherapy and postoperative radiation inthemanagement of malignant pleural mesothelioma. Int J. Radiat. Oncol. Biol. Phys 10: 325 - 331, 1984. 22) Rush V, Kelsen D, Salz L et al. A phase 2 trial of intrapleural and systemic chemotherapy after pleurectomy/decortication for malignant pleural mesothelioma (MPM) Proceedings of the American Society of Clinical Oncology 11: 352,1992. 23) Sugarbaker DJ, Lynch TJ, Strauss GM et al. Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin.Oncol 11 (6): 1172 - 1178, 1993. 24) Rush VW, Rosenzweig K, VenKatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122(4): 788-95, 2001. 25) Astoul P, Picat-Ioossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 83: 2099 - 104, 1998. 26) Castagneto B, Zai S, Mutti L, Palliative and therapeutic activity of IL-2 immunotherapty in unresectable malignant pleural mesothelioma with pleural effusion. Results of a phase II study on 31 consecutive patients.. Lung Cancer 31: 303-310, 2001. 27) Albelda SM, Gene therapy for lung cancer and mesothelioma. Chest 111: 144s-149s 1997. 28) Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural edenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 7 (12) : 1511-8 2000. 29) Pache JC, Ianssen YM, Walsh ES, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in respnse to long asbestos fibers. Am Pathol 152(2) 333-10,1998. 30) Strizzi S, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth in human malignant mesothelioma. J Pathol 193(4): 468-75.2001.
|
|
|
|
Potete inviare a